Kyverna Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Miv-cel showed rapid, durable, and clinically meaningful improvements in SPS and gMG, with a strong safety profile and the potential to eliminate chronic immunotherapies. Launch strategy targets high-need SPS patients at specialized centers, with robust physician support and regulatory momentum.
-
Transformative pivotal data for miv-cel in stiff person syndrome showed disease reversal and strong safety, with BLA filing and launch targeted for this year. Pipeline expansion includes myasthenia gravis and progressive MS, supported by robust manufacturing and a focused commercial strategy.
-
Transformative clinical results in SPS and MG have set the stage for a first-in-class CAR-T launch, with strong regulatory alignment, robust financials, and validated manufacturing. Expansion into additional autoimmune indications and next-generation platforms is underway.
Fiscal Year 2025
-
The phase II KYSA-8 trial of miv-cel in stiff person syndrome met all primary and secondary endpoints, showing rapid, durable, and clinically meaningful improvements in mobility and disability, with a favorable safety profile. These results support a BLA submission in 2026 and position miv-cel as a potential first-in-class therapy for SPS.
-
Pivotal clinical progress in CAR T therapy for autoimmune diseases is highlighted, with KYV-101 showing strong efficacy and safety in SPS and MG. First-mover advantage, robust financials, and a growing pipeline position the company for leadership in this space.
-
Interim phase II data for KYV-101 in gMG showed rapid, robust, and sustained efficacy, with all patients achieving clinically meaningful responses and most discontinuing immunosuppressants. The safety profile was manageable, and results support advancing to a well-powered phase III trial.
-
Late-stage CAR-T therapy development targets SPS and MG, with over 100 patients treated and pivotal trials advancing. KYV-101 shows durable, drug-free remissions and a strong safety profile, with expansion plans into MS and RA. Key data readouts and regulatory filings are expected in the next year.
-
Significant progress was highlighted in advancing CAR-T therapies for autoimmune diseases, with KYV-101 showing strong efficacy and durability in SPS and MG. Regulatory milestones, a focused commercial strategy, and a robust cash position support near-term launches and future expansion.
-
Significant progress is being made with pivotal trials for SPS and MG, with KYV-101 showing strong safety and efficacy, and a BLA filing for SPS expected in the first half of next year. Manufacturing capacity is expanding, and new data in MS and RA are anticipated later this year.
-
The event highlighted KYV-101's potential as a first-in-class CAR-T therapy for SPS and MG, with strong early clinical data showing durable, drug-free remission. Market analysis revealed significant unmet need and high cost burden, supporting a compelling commercial opportunity. The phase III MG trial is FDA-aligned, well-powered, and designed for rapid execution.
-
KYV-101 is advancing through pivotal trials for SPS and MG, with strong early results prompting FDA support for accelerated development. The therapy shows a favorable safety profile, durable patient outcomes, and significant market potential, with next-generation KYV-102 set for IND filing this year.
-
A differentiated CAR-T platform is advancing in autoimmune diseases, with transformative early results in SPS, MG, and LN. Pivotal SPS trial is over 40% enrolled, with top-line data and BLA filing expected in 2026. Manufacturing and regulatory strategies support rapid expansion and market entry.
-
The session outlined a focused strategy to advance CAR-T therapies for autoimmune diseases, with pivotal trials in SPS, MG, and LN, and a next-gen manufacturing platform (KYV102) targeting broader access and lower costs. Durable efficacy, strong safety, and regulatory momentum position the company for leadership in this space.